Cardinal Health expands Actinium-225 production to support theranostics growth

The move addresses a critical isotope supply constraint and reinforces the company’s role in the precision-oncology value chain.

United States: Cardinal Health announced on 1 April 2026 that it had significantly expanded its Actinium-225 production capabilities at its Center for Theranostics Advancement in Indianapolis. The company added a high-capacity production line to its Drug Master File, thereby increasing the supply of cGMP-compliant Ac-225 for investigational drug programmes and future commercial manufacturing. The significance of the announcement lies in the central role Ac-225 now plays in targeted alpha therapy, a field that has drawn substantial industry interest but has also faced persistent supply limitations. By raising production capacity, Cardinal Health is positioning itself not merely as a contract supplier, but as a strategic infrastructure provider to an emerging therapeutic segment.

The broader market context makes this development especially noteworthy. Radiopharmaceutical innovation is increasingly moving from niche oncology applications toward a more scalable precision-medicine model. However, the pace of clinical advancement often depends on reliable isotope sourcing. In that sense, Cardinal Health’s expansion helps strengthen one of the most important enabling layers beneath the theranostics ecosystem. By supporting more than 15 clinical trials globally to date, the company has already demonstrated relevance in this space, and the new capacity suggests a forward-looking strategy that anticipates increasing commercial demand as more programmes move closer to market.

According to Shane Thrasher, Vice President of Radiopharmaceutical Manufacturing, Cardinal Health Nuclear & Precision Health Solutions, “Expanding our Ac-225 production capacity is a critical step forward for the industry and for patients. As targeted alpha therapies progress through clinical trials, reliable access to Ac-225 remains essential. This expanded capacity strengthens our ability to meet customer needs today while preparing for significantly larger commercial volumes that may occur in the coming years.”